MECP2 and myelodysplastic syndrome: For example, SOX13 is normally up-regulated in MDS lines, and MECP2 ASO treatment restores this gene back to unaffected control levels and causes a down-regulation of SOX13 in MECP2 ASO-treated unaffected control lines (Fig. 5B).